ENGINEERED LIGAND-BASED ANTAGONISTS OF PLATELET-DERIVED GROWTH FACTOR RECEPTOR FOR TARGETED BREAST CANCER THERAPY
$564,075FY2011Department of DefenseDOD
The Leland Stanford Junior University
Investigators
View source on USAspending →ENGINEERED LIGAND-BASED ANTAGONISTS OF PLATELET-DERIVED GROWTH FACTOR RECEPTOR FOR TARGETED BREAST CANCER THERAPY · GrantIndex